Page 9 - Special Access News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The wholly-owned Creso Pharma subsidiary is currently conducting clinical trials of its synthetic psilocybin formulation as treatment for mental health conditions NEDLANDS, Australia, Feb. 9, 2023 /PRNewswire/ --Creso Pharma Limited(ASX:CPH, FRA:1X8) ('Creso Pharma') is pleased to announce its wholly-owned psychedelics subsidiary, Halucenex Life Sciences Inc. ('Halucenex'), is exploring opportunities to register its synthetic psilocybin formulation for the Australian market following recent regulatory changes. The Therapeutic Goods Administration (TGA), the medicine and therape...

07.02.2023 - The initial line of Viola-branded products will include proprietary formulations in vaporizer formats for patients with medical authorizations through the Special Access Program. The prescription products will be commercialized in partnership with ... Seite 1

Avicanna Inc (TSX:AVCN, OTCQX:AVCNF) announced that it has entered into a new sub-license agreement with VB Brands California LLC (Viola Brands) and Player...

Thomas Hartle has end-of-life anxiety stemming from a terminal cancer diagnosis, and in 2020, the 54-year-old became the first person in Canada to legally gain access to psilocybin-assisted therapy to deal with it.

Around Australia and the world, scientists, psychiatrists and CEOs are mapping out the potential of psychedelics. But not everyone’s on the same page.